PSA response and early PSA progression evaluated in patients randomized in a phase III trial comparing androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer (GETUG-AFU 15/0403).
G. Gravis
No relevant relationships to disclose
K. Fizazi
Employment or Leadership Position - Sanofi
F. Joly
No relevant relationships to disclose
S. Oudard
Employment or Leadership Position - Sanofi
F. Priou
No relevant relationships to disclose
I. Latorzeff
No relevant relationships to disclose
R. Delva
No relevant relationships to disclose
B. Esterni
No relevant relationships to disclose
M. Habibian
No relevant relationships to disclose
M. Soulie
No relevant relationships to disclose